Background: High blood pressure affects approximately 116 million adults in the United States. It is the leading risk factor for death and disability across the world. Unfortunately, over the past decade, hypertension control rates have decreased across the United States. Prediction models and clinical studies have shown that reducing clinician inertia alone is sufficient to reach the target of ≥80% blood pressure control. Digital health tools containing evidence‐based algorithms that are able to reduce clinician inertia are a good fit for turning the tide in blood pressure control, but careful consideration should be taken in the design process to integrate digital health interventions into the clinical workflow. Methods: We describe the development of a provider‐facing hypertension management platform. We enumerate key steps of the development process, including needs finding, clinical workflow analysis, treatment algorithm creation, platform design and electronic health record integration. We interviewed and surveyed 5 Stanford clinicians from primary care, cardiology, and their clinical care team members (including nurses, advanced practice providers, medical assistants) to identify needs and break down the steps of clinician workflow analysis. The application design and development stage were aided by a team of approximately 15 specialists in the fields of primary care, hypertension, bioinformatics, and software development. Conclusions: Digital monitoring holds immense potential for revolutionizing chronic disease management. Our team developed a hypertension management platform at an academic medical center to address some of the top barriers to adoption and achieving clinical outcomes. The frameworks and processes described in this article may be used for the development of a diverse range of digital health tools in the cardiovascular space.
Occupational and non-occupational risk factors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have been reported in healthcare workers (HCWs), but studies evaluating risk factors for infection among physician trainees are lacking. We aimed to identify sociodemographic, occupational, and community risk factors among physician trainees during the first wave of coronavirus disease 2019 (COVID-19) in New York City. In this retrospective study of 328 trainees at the Mount Sinai Health System in New York City, we administered a survey to assess risk factors for SARS-CoV-2 infection between 1 February and 30 June 2020. SARS-CoV-2 infection was determined by self-reported and laboratory-confirmed IgG antibody and reverse transcriptase-polymerase chain reaction test results. We used Bayesian generalized linear mixed effect regression to examine associations between hypothesized risk factors and infection odds. The cumulative incidence of infection was 20.1%. Assignment to medical-surgical units (OR, 2.51; 95% CI, 1.18–5.34), and training in emergency medicine, critical care, and anesthesiology (OR, 2.93; 95% CI, 1.24–6.92) were independently associated with infection. Caring for unfamiliar patient populations was protective (OR, 0.16; 95% CI, 0.03–0.73). Community factors were not statistically significantly associated with infection after adjustment for occupational factors. Our findings may inform tailored infection prevention strategies for physician trainees responding to the COVID-19 pandemic.
Risk factors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are not well-defined in resident physicians and fellows (trainees). We aimed to identify sociodemographic, occupational and community factors associated with SARS-CoV-2 infection among trainees during the first wave of the coronavirus disease 2019 (COVID-19) pandemic in New York City (NYC). In this retrospective cohort study, we administered an electronic survey between June 26 and August 31, 2020 to trainees at the Mount Sinai Health System in NYC to assess risk factors for SARS-CoV-2 infection between February 1 and June 30, 2020. We used Bayesian generalized linear mixed effect regression and structural equation models to examine associations. SAR-CoV-2 infection was determined by self-reported IgG antibody and reverse transcriptase-polymerase chain reaction results and confirmed with laboratory results. Among 2354 trainees invited to participate, 328 (14%) completed the survey and reported test results. The cumulative incidence of SARS-CoV-2 infection was 20.1%. Assignment to medical-surgical units (odds ratio [OR], 2.51; 95% CI, 1.18-5.34), and training in emergency medicine, critical care and anesthesiology (OR, 2.93; 95% CI, 1.24-6.92) were independently associated with infection. Deployment to care for unfamiliar patient populations was protective against infection (OR, 0.16; 95% CI, 0.03-0.73). Community factors were not significantly associated with infection after adjustment for occupational factors. Our findings may inform tailored infection prevention strategies for trainees responding to the COVID-19 pandemic.
Accurate prediction of SARS-CoV-2 infection based on symptoms can be a cost-efficient tool for remote screening in healthcare settings with limited SARS-CoV-2 testing capacity. We used a machine learning approach to determine self-reported symptoms that best predict a positive SARS-CoV-2 test result in physician trainees from a large healthcare system in New York. We used survey data on symptoms history and SARS-CoV-2 testing results collected retrospectively from 328 physician trainees in the Mount Sinai Health System, over the period 1 February 2020 to 31 July 2020. Prospective data on symptoms reported prior to SARS-CoV-2 test results were available from the employee health service COVID-19 registry for 186 trainees and analyzed to confirm absence of recall bias. We estimated the associations between symptoms and IgG antibody and/or reverse transcriptase polymerase chain reaction test results using Bayesian generalized linear mixed effect regression models adjusted for confounders. We identified symptoms predicting a positive SARS-CoV-2 test result using extreme gradient boosting (XGBoost). Cough, chills, fever, fatigue, myalgia, headache, shortness of breath, diarrhea, nausea/vomiting, loss of smell, loss of taste, malaise and runny nose were associated with a positive SARS-CoV-2 test result. Loss of taste, myalgia, loss of smell, cough and fever were identified as key predictors for a positive SARS-CoV-2 test result in the XGBoost model. Inclusion of sociodemographic and occupational risk factors in the model improved prediction only slightly (from AUC = 0.822 to AUC = 0.838). Loss of taste, myalgia, loss of smell, cough and fever are key predictors for symptom-based screening of SARS-CoV-2 infection in healthcare settings with remote screening and/or limited testing capacity.
BACKGROUND Hypertension affects nearly half of US adults, yet fewer than one in four achieves adequate blood pressure (BP) control. Traditional outpatient management is limited by infrequent visits and episodic BP measurement, contributing to therapeutic inertia. Remote patient monitoring (RPM) enables home-based BP tracking but can overwhelm clinicians with unstructured data, exacerbating administrative burden. Guideline-integrated decision support that automates BP interpretation and generates medication titration recommendations could reduce therapeutic inertia while preserving clinician oversight. OBJECTIVE This study was conducted to evaluate the feasibility, acceptability, and preliminary effectiveness of the HrtEx hypertension management platform in distinct care environments. METHODS We conducted two prospective single-arm pilot studies of HrtEx, a clinician-facing digital decision support platform that converts home BP data into guideline-concordant medication titration recommendations. The first pilot (HrtEx 1.0; n=18) was conducted at an urban academic medical center; the second (HrtEx 2.0; 19 enrolled, 15 analyzed) at a rural cardiology clinic. Adults with essential hypertension (BP >130/80 mmHg) treated with 2 or fewer antihypertensive medications measured home BP daily using Bluetooth-enabled cuffs with automated transmission. BP values were averaged over 2-week intervals; sustained elevations triggered guideline-based titration recommendations that clinicians could accept or decline. The primary outcome was 12-week change in systolic and diastolic BP; clinician acceptance rate of algorithm-generated recommendations was assessed as a secondary outcome in HrtEx 2.0. RESULTS In the academic pilot, mean systolic BP (SBP) decreased from 133.1 ± 7.8 to 121.3 mmHg (Δ −11.8 mmHg; 95% CI, 5.8 to 17.9; p<0.001) and mean diastolic BP (DBP) from 87.3 ± 7.1 to 80.2 mmHg (Δ −7.1 mmHg; 95% CI, 3.1 to 11.1; p=0.002). In the rural pilot, among the 15 participants with elevated baseline BP, mean SBP decreased from 133.9 to 124.7 mmHg (Δ −9.2 mmHg; 95% CI, 4.6 to 13.8; p=0.0008; d=1.10) and mean DBP from 79.0 to 76.1 mmHg (Δ −2.9 mmHg; 95% CI, 0.8 to 5.1; p=0.012; d=0.75). In Pilot 2, clinicians accepted 32 of 38 (84%) algorithm-generated titration recommendations, averaging 2.1 accepted adjustments per analyzed patient (32 accepted recommendations across 15 analyzed patients); clinician recommendation tracking was not implemented in Pilot 1. Patient adherence exceeded 89% in both cohorts; 100% of surveyed Pilot 2 participants expressed satisfaction with medication titration timing. CONCLUSIONS Across two geographically and demographically distinct single-arm pilot studies, a guideline-integrated RPM decision support platform demonstrated feasibility and was associated with systolic BP reductions of 11.8 mmHg and 9.2 mmHg in academic and rural cohorts, respectively, alongside high clinician acceptance and patient adherence. Given the absence of a comparator arm, these findings are hypothesis-generating and support confirmatory evaluation in randomized controlled trials. CLINICALTRIAL NCT05479461